Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 248-093-9 | CAS number: 26896-20-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://echa.europa.eu./o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Toxicological Summary
- Administrative data
- Workers - Hazard via inhalation route
- Workers - Hazard via dermal route
- Workers - Hazard for the eyes
- Additional information - workers
- General Population - Hazard via inhalation route
- General Population - Hazard via dermal route
- General Population - Hazard via oral route
- General Population - Hazard for the eyes
- Additional information - General Population
Administrative data
Workers - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 86 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: European Centre for Ecotoxicology and Toxicology of Chemicals Technical Report 110
- Overall assessment factor (AF):
- 6
- Dose descriptor starting point:
- NOAEL
- Value:
- 700 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 515.9 mg/m³
- Explanation for the modification of the dose descriptor starting point:
Substance specific information on oral absorption, but not inhalation absorption, is available for neodecanoic acid. A toxicokinetics study performed with14C-labelled neodecanoic acid in rats previously unexposed or preconditioned by five days of daily exposure to 100 mg/kg bw-d is available. The observed absorption of neodecanoic acid averaged ≥53.5% in male rats based on the recovery of 40.4% to 69.6% of the administered dose in urine. The observed absorption of neodecanoic acid averaged ≥41.8% in female rats based on the recovery of 32.9% to 69.6% of the administered dose in urine. Because fecal metabolites where not assessed it is impossible to tell if the fraction of the administered dose recovered in feces was absorbed or not. It is likely some fraction of fecally excreted compound was absorbed but eliminated via feces. This results in an underestimate of absorbed dose and thus a more conservative derivation of internal dose. Point of departure adjusted for oral absorption was slightly lower for female rats, thus that value is used to calcualte an absorption-adjusted NOAEL. Thus the NOAEL of 700 mg/kg-d multiplied by 41.8% oral absorption results in an absorption-adjusted NOAEL of 292.6 mg/kg/d.
The absorption-adjusted oral dose is converted to a corresponding air concentration using the standard breathing volume of a rat. The default physiological parameter under the allometric scaling principle from Table R.8 -2 for an eight hour exposure, 0.38 m3/kg bw was used. The absorption-adjusted NOAEL of 292.6 mg/kg/d is adjusted for respiration volume for rats (8 hours = 0.38 m^3/kg bw). The calculated rat NOAEC is therefore 292.6/0.38 = 770 mg/m^3.
The point of departure is further adjusted to account for differences between the 8 hour respiration volume of resting humans (6.7 m^3/person) and lightly working humans (10 m^3/person). The calculated value is 770 mg/m^3 * (6.7 m^3 per person / 10 m^3 per person) = 515.9 mg/m^3.
- AF for dose response relationship:
- 1
- Justification:
- No human relevant adverse effects identified at the highest tested dose in the study
- AF for differences in duration of exposure:
- 2
- Justification:
- This factor is the same suggested value in both ECETOC Technical Report 110 and ECHA's 2012 Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- ECETOC and ECHA guidance indicates not to apply an interspecies allometric scaling factor for oral-to-inhalation route-to-route extrapolation
- AF for other interspecies differences:
- 1
- Justification:
- No other potential assessment factor need identified
- AF for intraspecies differences:
- 3
- Justification:
- Estimates for the upper 95th percentile variability distribution for both toxicokinetic and -dynamic parameters were 4.3 for the dataset of Renwick and Lazarus ("Human variability and noncancer risk assessment – an analysis of the default uncertainty factor." Regul Toxicol Pharmacol 27:3-20, 1998) and 3.8 for Hattis et al ("Human interindividual variability in parameters related to health risks." Risk Anal 19(4):711-726, 1999). Because the worker population is more homogenous a lower factor of 3 is justified.
- AF for the quality of the whole database:
- 1
- Justification:
- All toxicology endpoints have been addressed through experimental data or read-across.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Workers - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 29 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: European Centre for Ecotoxicology and Toxicology of Chemicals Technical Report 110
- Overall assessment factor (AF):
- 24
- Dose descriptor starting point:
- NOAEL
- Value:
- 700 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 700 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The dose descriptor starting point is not modified (i.e., adjustment factor of 1) is used for oral to dermal extrapolation.
- AF for dose response relationship:
- 1
- Justification:
- No human relevant adverse effects identified at the highest tested dose in the study
- AF for differences in duration of exposure:
- 2
- Justification:
- This factor is the same suggested value in both ECETOC Technical Report 110 and ECHA's 2012 Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- This factor is the same suggested value in both ECETOC Technical Report 110 and ECHA's 2012 Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
- AF for other interspecies differences:
- 1
- Justification:
- Interspecies comparisons of rats and mice indicates an interspecies difference of 1.4 for these two species, a value closely corresponding to that calculated by allometry (7:4 = 1.75). This indicates an additional factor (e.g., 2.5) is not necessary, as interspecies differences are generally accounted for in allometric scaling. Further, because no adverse effects were observed there is no species-specific reason to expect differences between rats and humans.
- AF for intraspecies differences:
- 3
- Justification:
- Estimates for the upper 95th percentile variability distribution for both toxicokinetic and -dynamic parameters were 4.3 for the dataset of Renwick and Lazarus ("Human variability and noncancer risk assessment – an analysis of the default uncertainty factor." Regul Toxicol Pharmacol 27:3-20, 1998) and 3.8 for Hattis et al ("Human interindividual variability in parameters related to health risks." Risk Anal 19(4):711-726, 1999). Because the worker population is more homogenous a lower factor of 3 is justified.
- AF for the quality of the whole database:
- 1
- Justification:
- All toxicology endpoints have been addressed through experimental data or read-across.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
Workers - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - workers
Acute toxicity
A DNEL for acute toxicity should be derived if an acute hazard leading to acute toxicity (e.g. C&L) has been identified and there is a potential for high peak exposures. These “peaks” are normally associated with inhalation exposure but are less common for skin contact and ingestion (Appendix R.8-8). Neodecanoic acid is not classified for acute toxicity; oral, dermal or inhalation.
Irritation
Neodecanoic acid is not classified as a skin irritant. A DNEL is not required for this endpoint.
Sensitization
Neodecanoic acid is not classified as a sensitizer. A DNEL is not required for this endpoint.
Genetic toxicity
Neodecanoic acid is not classified as a genotoxic or mutagenic. A DNEL is not required for this endpoint.
Reproductive and Developmental toxicity
A DNEL was derived for risk characterization for an exposure-based adaptation in replace of an EOGRTS study. The RCRs were developed from DNELs derived from a modified three-generation reproduction study in rats NOAEL value; and therefore, is directly applicable to the information requirement. The DNELs were highly conservative for reproductive toxicity effects. There were no adverse findings at the highest dose tested. An oral DNEL was not derived because neodecanoic acid is not used in professional use or consumer products; and therefore, no wide dispersive applications are considered in this evaluation.
DNEL Derivation
Calculation of a Modified Point of Departure (Starting Point) by Route-to-Route Extrapolation (oral to inhalation)
An oral DNEL was not derived because neodecanoic acidis not used in professional use or consumer products; and therefore, no wide dispersive applications are considered in this evaluation. This product is used as an intermediate in the manufacturing of other substance. The substance when manufactured is generally handled in closed contained systems with occasional potential for exposures.
Inhalation
Dose descriptor = NOAEL of 75/mg/kg/day; from a well described 3-generation reproduction and development study
Route-to-route extrapolation (calculation B.3 in ECHA Guidance R.8)
inhalatory NOAEC = oral LOAEL * (1/ sRV rat 8h) * (ABS oral / ABS inh) * (sRV human / wRV)
inhalatory NOAEC= 75 * (1/0.38) * (100/100) * (6.7 / 10)
inhalatory NOAEC = 132.24 mg/m3
Adjustment factors (Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health):
Criteria |
Adjustment Factor |
Allometric scaling – rat |
2.5 |
Intraspecies - workers |
5 |
Subchronic study to Chronic |
2 |
Dose-response |
1 |
Database quality |
1 |
Overall Adjustment Factor |
25 |
DNEL calculation
DNEL inhalation = inhalation NOAEC / (adjustment factors)
DNEL inhalation = 132.24 mg/m3/ (25)
DNEL inhalation = 5.29 mg/m3
Dermal - Systemic
Dose descriptor = Dose descriptor = NOAEL of 75/mg/kg/day; from a well described 3-generation reproduction and development study
Modification of dose descriptor
dermal NOAEL = oral NOAEL * (animal exposure / worker exposure) * (animal days / worker days) *)(oral abs / dermal abs)
= 75 * (8 / 8) * (4 / 5)* (100 / 10)
dermal NOAEL = 600 mg/kg/day
Adjustment factors (Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health):
Criteria |
Adjustment Factor |
Allometric scaling - rat |
10 |
Intraspecies - workers |
5 |
Subchronic study to Chronic |
2 |
Dose-response |
1 |
Database quality |
1 |
Overall Adjustment Factor |
100 |
DNEL calculation
DNEL dermal = dermal NOAEL / (adjustment factors)
DNEL dermal = 600 mg/kg/day / (100)
DNEL dermal = 6 mg/kg/day
Long-term systemic effects
The potential of a substance to cause long-term systemic effects can judged based on the results of repeated dose toxicity testing.
General Population - Hazard via inhalation route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 25.79 mg/m³
- Most sensitive endpoint:
- repeated dose toxicity
DNEL related information
- DNEL derivation method:
- other: European Centre for Ecotoxicology and Toxicology of Chemicals Technical Report 110
- Overall assessment factor (AF):
- 10
- Dose descriptor starting point:
- NOAEL
- Value:
- 700 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEC
- Value:
- 257.9 mg/m³
- Explanation for the modification of the dose descriptor starting point:
Substance specific information on oral absorption, but not inhalation absorption, is available for neodecanoic acid. A toxicokinetics study performed with14C-labelled neodecanoic acid in rats previously unexposed or preconditioned by five days of daily exposure to 100 mg/kg bw-d is available. The observed absorption of neodecanoic acid averaged ≥53.5% in male rats based on the recovery of 40.4% to 69.6% of the administered dose in urine. The observed absorption of neodecanoic acid averaged ≥41.8% in female rats based on the recovery of 32.9% to 69.6% of the administered dose in urine. Because fecal metabolites where not assessed it is impossible to tell if the fraction of the administered dose recovered in feces was absorbed or not. It is likely some fraction of fecally excreted compound was absorbed but eliminated via feces. This results in an underestimate of absorbed dose and thus a more conservative derivation of internal dose. Point of departure adjusted for oral absorption was slightly lower for female rats, thus that value is used to calcualte an absorption-adjusted NOAEL. Thus the NOAEL of 700 mg/kg-d multiplied by 41.8% oral absorption results in an absorption-adjusted NOAEL of 292.6 mg/kg/d.
The absorption-adjusted oral dose is converted to a corresponding air concentration using the 24 -hour standard breathing volume of a rat. The default physiological parameter under the allometric scaling principle from Table R.8-2 for an 24 hour exposure, 1.15 m3/kg bw was used. The absorption-adjusted NOAEL of 292.6 mg/kg/d is adjusted for respiration volume for rats (1.15 m^3/kg bw). The calculated rat NOAEC is therefore 292.6/1.15 = 257.9 mg/m^3.
- AF for dose response relationship:
- 1
- Justification:
- No human relevant adverse effects identified at the highest tested dose in the study
- AF for differences in duration of exposure:
- 2
- Justification:
- This factor is the same suggested value in both ECETOC Technical Report 110 and ECHA's 2012 Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
- AF for interspecies differences (allometric scaling):
- 1
- Justification:
- ECETOC and ECHA guidance indicates not to apply an interspecies allometric scaling factor for oral-to-inhalation route-to-route extrapolation
- AF for other interspecies differences:
- 1
- Justification:
- No other potential assessment factor need identified
- AF for intraspecies differences:
- 5
- Justification:
- The 95th or the 90th percentile for the intraspecies AF of the general human population can be estimated as approximately 6 and 4, respectively (ECETOC Technical Report 110). This justifies a factor of 5 instead of 10.
- AF for the quality of the whole database:
- 1
- Justification:
- All toxicology endpoints have been addressed through experimental data or read-across.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard via dermal route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 17.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: European Centre for Ecotoxicology and Toxicology of Chemicals Technical Report 110
- Overall assessment factor (AF):
- 40
- Dose descriptor starting point:
- NOAEL
- Value:
- 700 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 700 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
The dose descriptor starting point is not modified (i.e., adjustment factor of 1) is used for oral to dermal extrapolation.
- AF for dose response relationship:
- 1
- Justification:
- No human relevant adverse effects identified at the highest tested dose in the study
- AF for differences in duration of exposure:
- 2
- Justification:
- This factor is the same suggested value in both ECETOC Technical Report 110 and ECHA's 2012 Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- This factor is the same suggested value in both ECETOC Technical Report 110 and ECHA's 2012 Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
- AF for other interspecies differences:
- 1
- Justification:
- Interspecies comparisons of rats and mice indicates an interspecies difference of 1.4 for these two species, a value closely corresponding to that calculated by allometry (7:4 = 1.75). This indicates an additional factor (e.g., 2.5) is not necessary, as interspecies differences are generally accounted for in allometric scaling. Further, because no adverse effects were observed there is no species-specific reason to expect differences between rats and humans.
- AF for intraspecies differences:
- 5
- Justification:
- The 95th or the 90th percentile for the intraspecies AF of the general human population can be estimated as approximately 6 and 4, respectively (ECETOC Technical Report 110). This justifies a factor of 5 instead of 10.
- AF for the quality of the whole database:
- 1
- Justification:
- All toxicology endpoints have been addressed through experimental data or read-across.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties have been identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
Local effects
Long term exposure
- Hazard assessment conclusion:
- no hazard identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
General Population - Hazard via oral route
Systemic effects
Long term exposure
- Hazard assessment conclusion:
- DNEL (Derived No Effect Level)
- Value:
- 17.5 mg/kg bw/day
- Most sensitive endpoint:
- repeated dose toxicity
- Route of original study:
- Oral
DNEL related information
- DNEL derivation method:
- other: European Centre for Ecotoxicology and Toxicology of Chemicals Technical Report 110
- Overall assessment factor (AF):
- 40
- Dose descriptor starting point:
- NOAEL
- Value:
- 700 mg/kg bw/day
- Modified dose descriptor starting point:
- NOAEL
- Value:
- 700 mg/kg bw/day
- Explanation for the modification of the dose descriptor starting point:
No modification is suggested because the source study is oral
- AF for dose response relationship:
- 1
- Justification:
- No human relevant adverse effects identified at the highest tested dose in the study
- AF for differences in duration of exposure:
- 2
- Justification:
- This factor is the same suggested value in both ECETOC Technical Report 110 and ECHA's 2012 Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
- AF for interspecies differences (allometric scaling):
- 4
- Justification:
- This factor is the same suggested value in both ECETOC Technical Report 110 and ECHA's 2012 Guidance on information requirements and chemical safety assessment Chapter R.8: Characterisation of dose [concentration]-response for human health.
- AF for other interspecies differences:
- 1
- Justification:
- Interspecies comparisons of rats and mice indicates an interspecies difference of 1.4 for these two species, a value closely corresponding to that calculated by allometry (7:4 = 1.75). This indicates an additional factor (e.g., 2.5) is not necessary, as interspecies differences are generally accounted for in allometric scaling. Further, because no adverse effects were observed there is no species-specific reason to expect differences between rats and humans.
- AF for intraspecies differences:
- 5
- Justification:
- The 95th or the 90th percentile for the intraspecies AF of the general human population can be estimated as approximately 6 and 4, respectively (ECETOC Technical Report 110). This justifies a factor of 5 instead of 10.
- AF for the quality of the whole database:
- 1
- Justification:
- All toxicology endpoints have been addressed through experimental data or read-across.
- AF for remaining uncertainties:
- 1
- Justification:
- No remaining uncertainties identified
Acute/short term exposure
- Hazard assessment conclusion:
- no hazard identified
DNEL related information
General Population - Hazard for the eyes
Local effects
- Hazard assessment conclusion:
- no hazard identified
Additional information - General Population
Acute toxicity
A DNEL for acute toxicity should be derived if an acute hazard leading to acute toxicity (e.g. C&L) has been identified and there is a potential for high peak exposures. These “peaks” are normally associated with inhalation exposure but are less common for skin contact and ingestion (Appendix R.8-8). Neodecanoic acid is not classified for acute toxicity; oral, dermal or inhalation.
Irritation
Neodecanoic acid is not classified as a skin irritant. A DNEL is not required for this endpoint.
Sensitization
Neodecanoic acid is not classified as a sensitizer. A DNEL is not required for this endpoint.
Genetic toxicity
Neodecanoic acid is not classified as a genotoxic or mutagenic. A DNEL is not required for this endpoint.
Reproductive and Developmental toxicity
Neodecanoic acid is not classified as a reproductive or developmental toxin. A DNEL is not required for this endpoint.
Long-term systemic effects
The potential of a substance to cause long-term systemic effects can judged based on the results of repeated dose toxicity testing.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)